Factores pronósticos en los tumores de origen ginecológico

ANALES DEL SISTEMA SANITARIO DE NAVARRA

Suplemento 1

Factores pronósticos en los tumores de origen ginecológico
Prognostic factors in tumours of gynaecological origin

R. Vera, E. Prujá, M. Marcos, J.J. Albistur, M. Tejedor, J.J. Valerdi

Servicio de Oncología. Hospital de Navarra. Pamplona

BIBLIOGRAFÍA

1. Casagrande JT, Louie EV, Pike MC, Ross RK, Henderson BE. Incessant ovulation in ovarian cancer. Lancet 1979; 2:170-173.

2. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138-1150.

3. van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Neijt JP. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989; 7: 769-773.

4. Thigpen T, Brady MF, Omura GA, Creasman WT, Mc Guire WP, Hoskins WJ et al. Age as a prognostic factor in ovarian carcinoma. Cancer 1993; 71(2 Suppl): 606-614.

5. Swenerton KD, Hislop TG, Spinelli J, Le Riche JC, Yang N, Boyes DA. Ovarian carcinoma: A multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65: 264-269.

6. Sorbe B, Frankendal B, Veress B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 1982; 59: 576-582.

7. Piver MS. Importance of proper staging in ovarian cancer. Clin Obstet Gynecol 1983: 10: 223-234.

8. Hoskins WJ. The influence of cytoreductive surgery on progression-free interval and survival in epitelial ovarian cancer. Baillieres Clin Obstet and Gynecol 1989; 3: 59-71.

9. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Ntl Cancer Ins Monogr 1975; 42:101-104.

10. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992; 44: 207-212.

11. Volm M, Bruggemann A, Gunther M, Kleine W, Pfleiderer A, Vogt-Schaden M. Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma.Cancer Res 1985; 45: 5180-5185.

12. van der Zee AGJ, Hollema H, Suurmeijer AJH, Krans M, Sluiter WJ, Willense PHB et al. Value of p-glycoprotein, glutathione s-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13:70-78.

13. Heimburg S, Oehler MK, Papadopoulos T, Caffier H, Kristen P, Dietl J. Prognostic relevance of the endothelial marker CD 34 in ovarian cancer. Anticancer Res 1999; 19: 2527-2529.

14. Baekelandt M, Holm R, Nesland JM, Tropé CG, KristensenGB. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol 2000: 18: 3775-3781.

15. Zaino RJ, Kurman R, Herbold D, Gliedman J, Bundy BN, Voet R et al. The significance of squamous differentiation in endometrial carcinoma. Cancer 1991; 68: 2293-2302.

16. Gusberg SB. Virulence factors in endometrial cancer. Cancer 1993; 71(4 Suppl): 1464-1466.

17. Ingram SS, Rosenman J, Heath R, Morgan TM, Moore D, Varia M. The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys 1989; 17: 21-27.

18. Creasman WT: Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993; 71(4 Suppl): 1467-1470.

19. Friberg LG, Noren H, Delle U. Prognostic value of DNA ploidy and S-phase fraction in endometrial cancer stage I and II: a prospective 5-year survival study. Gynecol Oncol 1994; 53: 64-69.

20. PC, Cha SS, Podratz KC. HER-2/neu expression: a major prognosis factor in endometrial cancer. Gynecol Oncol 1992; 47: 179-185.

21. Seki N, Kodama J, Hongo A, Miyagi Y, Yoshinouchi M, Kudo T. Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in endometrial cancer. Int J Oncol 1999; 15: 781-786.

22. Obermair A, Tempfer C, Wasicky R, Kaider A, Hefler L, Kainz C. Prognostic significance of tumor angiogenesis in endometrial cancer. Obstet Gynecol 1999; 93: 367-371.

23. Wilczynski SP, Bergen S, Walker J, Liao SY, Pearlman LF. Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types. Hum Pathol 1988 ; 19: 697-704.

24. Young age as a prognostic factor in cervical cancer: results of a population-based study. Am J Obstet Gynecol 1999; 180: 1464-1467.

25. Prempree T, Patanaphan V, Sewchanel W, Scoth RM. The influence of patient´s age and tumor grade on the prognosis of carcinoma of the cervix. Cancer 1983; 51: 1764-1771.

26. Fletcher GH, Rutledge FN. Extended field technique in the management of the cancers of uterine cervix. Am J Roentgenol 1972; 114: 116-122.

27. Thomas GM. Improved treatment for cervical cancer - concurrent chemotherapy and radiotherapy. N Engl J Med 1999; 340: 1198-1200.

28. Jampolis S, Andras J, Flecher GH. Analysis of sites and causes of failures of irradiation in invasive squamous cell carcinoma of the intact uterine cervix. Radiology 1975; 15: 681-685.

29. Lanciano RM, Won M, Hanks GE. A reappraisal of the International Federation of Gynecology and Obstetrics staging system for cervical cancer: a study of patterns of care. Cancer 1992; 69: 482-487.

30. Kovalic JJ, Grigsby PW, Lockett MA. Cervical stump carcinoma. Int J Radiat Oncol Biol Phys 1991; 20: 933-938.

31. Noguchi H, Shiozawa I, Kitahara T, Yamazaki T, Fukuta T. Uterine body invasion of carcinoma of the uterine cervix as seen from surgical specimen. Gynecol Oncol 1988; 30: 173-182.

32. Prempree T, Patanaphan V, Viravathana T, Sewchanel W, Cho Y, Scott R. Radiation treatment of carcinoma of the cervix with extension into the endometrium: a reappraisal of its significance. Cancer 1982; 49: 2015-2020.

33. Stehman FB, Bundy BN, Di Saia PJ, Keys HM, Larson JE, Foeler WC. Carcinoma of the cervix treated with radiation therapy I: A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991; 67: 2776-2785.

34. Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with Stage IB cervical carcinoma. Gynecol Oncol 1995; 59: 38-44.

35. Young RH, Scully RE. Villoglandular papillary adenocarcinoma of the uterine cervix: a clinicopathologic analysis of 13 cases. Cancer 1989; 63: 1773-1779.

36. Ferry JA, Scully RE. "Adenoid cystic" carcinoma and adenoid basal cell carcinoma of the uterine cervix: a study of 28 cases. Am J Surg Pathol 1988; 12: 134-144.

37. Barnes W, Delgado G, Kurman RJ, Petrilli ES, Smith DM, Ahmed S et al. Posible prognostic significance of human papillomavirus type in cervical cancer. Gynecol Oncol 1988; 29: 267-273.

38. Suzuki M, Tsukagoshi S, Saga Y, Ohwada M, Sato I. Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology 1999; 57: 50-54.

39. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in aerly-stage invasive cervical cancer. Cancer Res 2000; 60: 4693- 4696.

40. Eddy GL, Marks RD, Miller MC, Underwood PB. Primary invasive vaginal carcinoma. Am J Obstet Gynecol 1991; 165: 292-298.

41. Prempree T. Role of radiation therapy in the manegement of primary carcinoma of the vagina. Acta Radiol Oncol 1982; 21: 195-201.

42. Chyle V, Zagars GK, Wheeler JA, Wharton JT, Delclos L. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 1996; 35: 891-905.

43. Kucera H, Vavra N. Radiation management of primary carcinoma of the vagina: clinical and histopathological variables associated with survival. Gynecol Oncol 1991; 40: 12-16.

44. Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1991; 164: 997-1004.

45. Mariani L, Conti L, Atlante G, Sciarretta F, Pozzi M, Vercillo M et al. Vulvar squamous carcinoma: prognostic role of DNA content. Gynecol Oncol 1998; 71: 159-164.

46. Boyce J, Fruchter RG, Kasambilides E, Nicastri AD, Sedlis A, Remy JC. Prognostic factors in carcinoma of the vulva. Gynecol Oncol 1991; 20: 364-1004.

47. Sedlis A, Homesley H, Bundy BN, Marshall R, Yordan E, Hacker N et al. Positive groin lymph nodes in superficial squamous cell vulvar cancer: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1987; 156: 1159-1164.

48. Binder SW, Huang I, Fu YS, Hacker NF, Berek JS. Risk factors for the developement of lynph node metastasis in vulvar squamous cell carcinoma. Gynecol Oncol 1990; 37: 9-16.